Olsson B, Johansson M, Gabrielsson J, Bolme P
Research and Development Department, ACO Läkemedel AB, Solna, Sweden.
Eur J Clin Pharmacol. 1988;34(1):77-82. doi: 10.1007/BF01061422.
The pharmacokinetics and bioavailability of N-acetylcysteine (NAC) have been determined after its intravenous and oral administration to 6 healthy volunteers. According to a randomized cross-over design each subject received NAC 200 mg i.v. and 400 mg p.o., and blood samples were collected for 30 h. Reduced NAC had a volume of distribution (VSS) of 0.59 l.kg-1 and a plasma clearance of 0.84 l.h-1.kg-1. The terminal half-life after intravenous administration was 1.95 h. The oral bioavailability was 4.0%. Based on total NAC concentration, its volume of distribution (VSS) was 0.47 l.kg-1 and its plasma clearance was 0.11 l.h-1.kg-1. The terminal half-life was 5.58 h after intravenous administration and 6.25 h after oral administration. Oral bioavailability of total NAC was 9.1%.
对6名健康志愿者静脉注射和口服N-乙酰半胱氨酸(NAC)后,测定了其药代动力学和生物利用度。按照随机交叉设计,每名受试者接受200mg静脉注射NAC和400mg口服NAC,并采集30小时的血样。还原型NAC的分布容积(VSS)为0.59L·kg-1,血浆清除率为0.84L·h-1·kg-1。静脉注射后的终末半衰期为1.95小时。口服生物利用度为4.0%。基于总NAC浓度,其分布容积(VSS)为0.47L·kg-1,血浆清除率为0.11L·h-1·kg-1。静脉注射后的终末半衰期为5.58小时,口服后的终末半衰期为6.25小时。总NAC的口服生物利用度为9.1%。